ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/21/21
Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACADPRNewsWire • 04/20/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law ViolationsNewsfile Corp • 04/14/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigation ACAD for Possible Securities Law ViolationsNewsfile Corp • 04/08/21
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock DriversBenzinga • 04/06/21
Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.PRNewsWire • 04/06/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its AttorneysPRNewsWire • 04/06/21
Acadia Stock Crashes After FDA Rejects Key Drug — Analyst Sees Huge DelayInvestors Business Daily • 04/05/21
Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related PsychosisBenzinga • 04/05/21
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related PsychosisBusiness Wire • 04/05/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADNewsfile Corp • 03/15/21
DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 03/10/21
Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In DementiaBenzinga • 03/09/21
Acadia plummets 49% after FDA decision dims chances of label expansion for key drug (ACAD)Business Insider • 03/09/21